Curated News
By: NewsRamp Editorial Staff
February 17, 2026
NeuroOne's OneRF System Gains Momentum with 50% of Ablations in Q1 2026
TLDR
- NeuroOne's OneRF system adoption grew with 50% of all ablations in Q1 2026, offering competitive advantages in new pain treatment markets with FDA-cleared technology.
- The OneRF system uses radiofrequency ablation technology with FDA 510(k) clearance, treating nine trigeminal neuralgia cases successfully and expanding through strategic partnerships and patent protection.
- NeuroOne's technology improves patient outcomes by providing pain-free results for neurological disorders, reducing invasive surgeries and offering better quality of life through advanced medical solutions.
- A professional pianist resumed his career after receiving a NeuroOne ablation, demonstrating the system's real-world impact on restoring patients' abilities and livelihoods.
Impact - Why it Matters
This news matters because NeuroOne's technological advancements represent significant progress in treating debilitating neurological conditions that affect millions worldwide. The successful treatment of trigeminal neuralgia patients, with all nine cases reportedly pain-free, offers hope for those suffering from severe facial pain who have limited treatment options. The company's expansion into new markets for lower back pain, spinal cord stimulation, and drug delivery for brain tumors addresses critical unmet medical needs that impact quality of life and healthcare costs. As NeuroOne advances its FDA-cleared technologies and expands its intellectual property portfolio, it positions itself to transform neurological care by offering minimally invasive alternatives to pharmaceutical treatments and invasive surgeries, potentially reducing hospitalizations and improving patient outcomes across multiple conditions.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has reported significant progress in its first quarter fiscal 2026 results, demonstrating growing adoption of its innovative medical technologies. The company's OneRF® Ablation System has achieved a milestone, with nearly 50% of all ablations since its 2024 launch occurring in Q1 2026, indicating accelerating market acceptance. Following FDA 510(k) clearance for the OneRF® Trigeminal Nerve Ablation System to treat facial pain, NeuroOne has successfully completed nine cases with all patients reportedly pain-free, marking entry into a completely new market. The company expects product revenue to reach at least $10.5 million in fiscal 2026, representing a 17% increase over the previous year, while advancing discussions with potential tier-one strategic partners for multiple new applications.
Key developments include the expansion of the company's intellectual property portfolio with key patents secured in the U.S. and Europe, now totaling 13 issued and pending patents domestically and 4 internationally. NeuroOne is making substantial progress across multiple programs, including a drug delivery system targeting glioblastomas that's ahead of schedule for commercial readiness in Q3 fiscal 2026, spinal cord stimulation percutaneous paddle lead studies beginning in Q2 fiscal 2026, and validation of the Basivertebral Nerve Ablation System for lower back pain through advisory board meetings. CEO Dave Rosa emphasized the momentum across all target markets, noting that doctors from the Mayo Clinic in Jacksonville, Florida provided positive experience with the system at the American Epilepsy Society Meeting, and a professional pianist from Chicago was able to resume his career after receiving an ablation with the system.
Financially, the company reported product revenue of $2.9 million for Q1 fiscal 2026, with product gross profit of $1.6 million (54.2% margin), though this represented a net loss of $1.4 million compared to net income of $1.8 million in the same quarter last year due to the absence of license revenue from the Zimmer distribution agreement. NeuroOne ended the quarter with $3.6 million in cash and believes it is funded through fiscal 2026, potentially longer if certain milestones are achieved. The company continues to make progress on ISO 13485 certification for outside the U.S. distribution and has scheduled a second audit in April 2026 with its notified body, while also establishing a physician advisory board to evaluate the treatment of glioblastomas for its drug delivery program.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne's OneRF System Gains Momentum with 50% of Ablations in Q1 2026
